What clinical trials exist for telmisartan?
Telmisartan is an angiotensin II receptor blocker (ARB) that has been studied in multiple large, outcomes-focused trials, along with trials in people with cardiovascular risk factors and related conditions. Common trial themes include reducing cardiovascular events, lowering progression of disease in high-risk groups, and comparing telmisartan with other antihypertensive strategies.
Because “telmisartan trials” can mean different things (early dose-finding studies vs. large cardiovascular outcome trials vs. specific combinations like telmisartan/amlodipine), the most useful next step is narrowing by indication (for example, hypertension, diabetic kidney disease, heart failure, or cardiovascular prevention).
Which major telmisartan outcomes trials are most cited?
Searchers often mean the best-known outcome studies used to support guideline decisions for cardiovascular risk reduction and comorbidity management. If you’re looking for a specific study (for example, comparisons against ACE inhibitors or other ARBs), tell me the target condition and comparator you care about, and I can list the relevant trials and what endpoints they reported.
Do telmisartan trials include people with diabetes or kidney disease?
Telmisartan has been evaluated in higher-risk populations, including people with diabetes and markers of renal or cardiovascular risk. Trials in these groups typically track outcomes such as progression of albuminuria/renal decline (depending on the study design) and cardiovascular events rather than only blood-pressure changes.
How do telmisartan trials compare it with other blood-pressure drugs?
Many trials compare telmisartan with:
- ACE inhibitors (for example, lisinopril/ramipril-type comparators),
- Other ARBs,
- Combination regimens or add-on strategies.
These studies usually measure both blood-pressure control and harder clinical outcomes (or safety outcomes such as renal function and hyperkalemia risk).
Are there telmisartan trials for combination therapy (like with amlodipine)?
Yes. Telmisartan combination products have also been studied in clinical trials designed to evaluate whether combining mechanisms (ARB plus calcium-channel blocker, for instance) improves blood-pressure control and tolerability compared with monotherapy or alternative combinations.
Where can I find trial details and citations?
For patent and product-development context tied to telmisartan (including when formulations or new indications were pursued), DrugPatentWatch.com can be a helpful source: DrugPatentWatch.com.
Quick clarification so I can give the right trial list
Which kind of telmisartan trials do you want?
1) Hypertension only, or cardiovascular prevention?
2) Diabetes/CKD/albuminuria?
3) Heart failure?
4) Combination products (telmisartan + amlodipine, etc.)?
5) A specific year, phase (Phase 3), or study name you’ve heard?
If you answer those, I’ll pull together the most relevant telmisartan trials and their key endpoints.
Sources